DOCSLIB.ORG

851 Genes from Wild Peromyscus Liver Showed Significant Differential Expression Gene Symbol Genbank Description 0610006A03rik BG

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
851 Genes from Wild Peromyscus Liver Showed Significant Differential Expression Gene Symbol Genbank Description 0610006A03rik BG 851 genes from wild Peromyscus Liver showed significant differential expression Gene Symbol Genbank Description 0610006A03Rik BG084074 RIKEN cDNA 0610006A03 gene 0610010D24Rik BG069698 RIKEN cDNA 0610010D24 gene 0610012H03Rik C86087 RIKEN cDNA 0610012H03 gene 0610040D20Rik BG071645 RIKEN cDNA 0610040D20 gene 1110004F14Rik AI843901 Transcribed locus 1110005A03Rik AI836508 RIKEN cDNA 1110005A03 gene 1110008P14Rik AI413491 RIKEN cDNA 1110008P14 gene 1110017I16Rik AI413224 RIKEN cDNA 1110017I16 gene 1110031I02Rik AU043030 RIKEN cDNA 1110031I02 gene 1110032D12Rik AI846771 Transcribed locus 1110039B18Rik AI841294 RIKEN cDNA 1110039B18 gene 1110059H15Rik BG063102 RIKEN cDNA 1110059H15 gene 1110063F24Rik AI843727 RIKEN cDNA 1110063F24 gene 1110065P20Rik AI413621 RIKEN cDNA 1110065P20 gene 1500003O03Rik BG082833 RIKEN cDNA 1500003O03 gene 1600029D21Rik BG063464 RIKEN cDNA 1600029D21 gene 1700001C02Rik AI414719 RIKEN cDNA 1700001C02 gene 1700020D05Rik BG088854 RIKEN cDNA 1700020D05 gene 1700034H14Rik BG088118 RIKEN cDNA 1700034H14 gene 2210401J11Rik BG069270 RIKEN cDNA 2210401J11 gene 2310005N03Rik AI843155 RIKEN cDNA 2310005N03 gene 2410025L10Rik AI839046 RIKEN cDNA 2410025L10 gene 2610019A05Rik BG074588 RIKEN cDNA 2610019A05 gene 2610205H19Rik BG082594 RIKEN cDNA 2610205H19 gene 2700069I18Rik AI414193 RIKEN cDNA 2700069I18 gene 2700078E11Rik AI851562 RIKEN cDNA 2700078E11 gene 2810003C17Rik BG080895 RIKEN cDNA 2810003C17 gene 2900042E01Rik AI415188 RIKEN cDNA 2900042E01 gene 2900073G15Rik BG084591 RIKEN cDNA 2900073G15 gene 2900097C17Rik BG073867 RIKEN cDNA 2900097C17 gene 3300001M20Rik BG070569 RIKEN cDNA 3300001M20 gene 4121402D02Rik BG069067 RIKEN cDNA 4121402D02 gene 4632417K18Rik BG069529 RIKEN cDNA 4632417K18 gene 4632419K20Rik AI841280 RIKEN cDNA 4632419K20 gene 4632428N05Rik BG077031 RIKEN cDNA 4632428N05 gene 4632434I11Rik BG083353 RIKEN cDNA 4632434I11 gene 4921506J03Rik AI840618 Transcribed locus 4921513D23Rik AI843592 RIKEN cDNA 4921513D23 gene 4930521E07Rik BG071199 RIKEN cDNA 4930521E07 gene 4933421E11Rik BG076885 RIKEN cDNA 4933421E11 gene 4933425L03Rik BG075891 Transcribed locus 4933433K01Rik BG074852 RIKEN cDNA 4933433K01 gene 5031439G07Rik BG064243 RIKEN cDNA 5031439G07 gene 5031439G07Rik BG087497 RIKEN cDNA 5031439G07 gene 5730442A20Rik BG077044 Transcribed locus 6430547I21Rik AI415354 RIKEN cDNA 6430547I21 gene 6430570G24 BG069663 Hypothetical protein 6430570G24 9030416H16Rik BG067505 RIKEN cDNA 9030416H16 gene 9330102E08Rik BG068979 RIKEN cDNA 9330102E08 gene 9430010O03Rik AU043039 RIKEN cDNA 9430010O03 gene 9430038I01Rik BG071786 RIKEN cDNA 9430038I01 gene A2bp1 AI841023 Ataxin 2 binding protein 1 A730082K24Rik BG070074 RIKEN cDNA A730082K24 gene Abca1 AI845514 ATP-binding cassette, sub-family A (ABC1), member 1 Abcc1 BG066832 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Acadl C79809 Acyl-Coenzyme A dehydrogenase, long-chain Acadm BG065314 Acyl-Coenzyme A dehydrogenase, medium chain Acat1 BG083405 Acetyl-Coenzyme A acetyltransferase 1 Acsl4 BG069344 Acyl-CoA synthetase long-chain family member 4 Acsl4 AI846046 Acyl-CoA synthetase long-chain family member 4 Acsl5 BG084205 Acyl-CoA synthetase long-chain family member 5 Actb BG062949 Actin, beta, cytoplasmic Actb BG077678 Actin, beta, cytoplasmic Actg1 BG072752 Actin, gamma, cytoplasmic 1 Actl6a BG064976 Actin-like 6A Actr10 BG064901 ARP10 actin-related protein 10 homolog (S. cerevisiae) Acvr1 AI528798 Activin A receptor, type 1 Adam8 BG069799 A disintegrin and metallopeptidase domain 8 Adamts4 BG078006 A disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 4 Adarb2 AI837690 Adenosine deaminase, RNA-specific, B2 Adh5 BG064803 Alcohol dehydrogenase 5 (class III), chi polypeptide Adk BG065190 Adenosine kinase Adm BG063462 Adrenomedullin Adm BG063461 Adrenomedullin Adm BG063079 Adrenomedullin AF013969 AU016279 Expressed sequence AF013969 Agrn AI324833 Agrin Agt BG088170 Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AI256396 BG074466 EST AI256396 AI851453 AI851453 Expressed sequence AI851453 Akt1 AI843381 Thymoma viral proto-oncogene 1 Akt2 AI843689 Thymoma viral proto-oncogene 2 Alas2 BG088378 Aminolevulinic acid synthase 2, erythroid Aldh1a1 BG086656 Aldehyde dehydrogenase family 1, subfamily A1 Aldh6a1 AW537342 Aldehyde dehydrogenase family 6, subfamily A1 Amigo3 AI413948 Adhesion molecule with Ig like domain 3 Anapc7 BG064663 Anaphase promoting complex subunit 7 Angel2 AI845692 Angel homolog 2 (Drosophila) Ank BG065715 Progressive ankylosis Ankrd11 AW551596 Ankyrin repeat domain 11 Ankrd12 BG086457 Ankyrin repeat domain 12 Ankrd15 AA409025 Ankyrin repeat domain 15 Anks1b BG082169 Ankyrin repeat and sterile alpha motif domain containing 1B Anp32b BG065023 acidic nuclear phosphoprotein 32 family, member B Anxa11 BG066718 Annexin A11 Anxa7 BG079480 Annexin A7 Aph1c C88059 Anterior pharynx defective 1c homolog (C. elegans) Arfrp1 BC010713 ADP-ribosylation factor related protein 1 Arhgap29 BG087019 Rho GTPase activating protein 29 Arhgap5 BG070137 Rho GTPase activating protein 5 Arhgef11 AU040633 Rho guanine nucleotide exchange factor (GEF) 11 Arhgef11 BG071208 Rho guanine nucleotide exchange factor (GEF) 11 Arl5a BG076736 ADP-ribosylation factor-like 5A Arl5a AI845892 ADP-ribosylation factor-like 5A Arl6ip1 AI843174 ADP-ribosylation factor-like 6 interacting protein 1 Arl6ip2 BG068644 ADP-ribosylation factor-like 6 interacting protein 2 Arl8b BG079579 ADP-ribosylation factor-like 8B Asah1 AI413346 N-acylsphingosine amidohydrolase 1 Ascc1 AW556196 Activating signal cointegrator 1 complex subunit 1 Ash2l BG078457 Ash2 (absent, small, or homeotic)-like (Drosophila) Asph BG070767 Aspartate-beta-hydroxylase Astn2 BG068842 Astrotactin 2 Atf4 BG086322 Activating transcription factor 4 Atp1b1 AW544616 ATPase, Na+/K+ transporting, beta 1 polypeptide Atp1b1 AI841308 ATPase, Na+/K+ transporting, beta 1 polypeptide Atp1b3 BG073136 ATPase, Na+/K+ transporting, beta 3 polypeptide Atp2a2 BG085195 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 Atp5c1 BG072870 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 AU015850 BG069973 Expressed sequence AU015850 AU023851 BG070457 Expressed sequence AU023851 AU045717 BG071977 Expressed sequence AU045717 Aurkb BG076440 Aurora kinase B Auts2 BG075604 Autism susceptibility candidate 2 AW907654 BG074275 7 days embryo whole body cDNA, RIKEN full-length enriched library, clone:C430040N23 product:unclassifiable, full insert sequence B230308N11Rik BG074850 RIKEN cDNA B230308N11 gene B230312A22Rik AI846579 RIKEN cDNA B230312A22 gene B4galt1 BG072304 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 Bace1 BG072311 Beta-site APP cleaving enzyme 1 Bax AI323521 Bcl2-associated X protein Baz1a BG079668 Bromodomain adjacent to zinc finger domain 1A BC003940 AW556496 CDNA sequence BC003940 BC004853 BG072402 CDNA sequence BC004853 BC008163 BG069471 CDNA sequence BC008163 BC010304 BG063475 CDNA sequence BC010304 BC010801 AI837701 CDNA sequence BC010801 BC035044 BG075534 CDNA sequence BC035044 BC055107 AI836637 CDNA sequence BC055107 Bcas3 BG069216 Breast carcinoma amplified sequence 3 Bcat1 BG084158 Branched chain aminotransferase 1, cytosolic Bex1 BG064920 Brain expressed gene 1 Bfar AI843158 Bifunctional apoptosis regulator Bmp4 BG078804 Bone morphogenetic protein 4 Bysl BG085216 Bystin-like C1r BG087171 Complement component 1, r subcomponent C78076 C78076 expressed sequence C78076 C78532 BG066233 Expressed sequence C78532 C78541 AI840742 expressed sequence C78541 C79267 BG079664 Expressed sequence C79267 C79267 AI843602 Expressed sequence C79267 C81431 BG067065 expressed sequence C81431 C86345 BG067437 expressed sequence C86345 C86400 BG080525 expressed sequence C86400 C87414 BG071984 Expressed sequence C87414 C920006C10Rik BG076854 RIKEN cDNA C920006C10 gene Calm1 BG072244 Calmodulin 1 Calm2 BG076848 Calmodulin 2 Camk1d AI846767 Transcribed locus Camk2g BG075454 Calcium/calmodulin-dependent protein kinase II gamma Camk2n2 AI840581 Calcium/calmodulin-dependent protein kinase II inhibitor 2 Camta1 BG075239 Calmodulin binding transcription activator 1 Canx BG077365 Calnexin Capza1 BG084305 Capping protein (actin filament) muscle Z-line, alpha 1 Capza1 NM_00979 Capping protein (actin filament) muscle Z-line, alpha 1 Cart1 BG078271 Cartilage homeo protein 1 Ccar1 BG064739 Cell division cycle and apoptosis regulator 1 Ccdc106 AI846455 Coiled-coil domain containing 106 Ccdc117 BG067350 CDNA sequence BC018601 Ccdc16 BG084881 Coiled-coil domain containing 16 Ccdc91 AI842497 Coiled-coil domain containing 91 Ccdc95 BG065288 Coiled-coil domain containing 95 Ccnb1 BG071965 Cyclin B1 Ccni BG075647 Cyclin I Ccnl1 AI843526 Cyclin L1 Cct4 AW555585 Chaperonin subunit 4 (delta) Cd2ap BG086246 CD2-associated protein Cd2bp2 BG072111 CD2 antigen (cytoplasmic tail) binding protein 2 Cdc23 BG073882 CDC23 (cell division cycle 23, yeast, homolog) Cdc42 BG075478 Cell division cycle 42 homolog (S. cerevisiae) Cdc5l BG065644 Cell division cycle 5-like (S. pombe) Cdc6 BG077012 Cell division cycle 6 homolog (S. cerevisiae) Cdh22 BG071796 Cadherin 22 Cdkn3 BG085641 Cyclin-dependent kinase inhibitor 3 Cds2 AI836183 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 Centb2 AI415346 Centaurin, beta 2 Centg2 AI414200 Centaurin, gamma 2 Cep27 BG069669 Centrosomal protein 27 Cflar BG068020 CASP8 and FADD-like apoptosis regulator Chd7 BG074854 Transcribed locus Chmp2b BG084517 Chromatin modifying protein 2B Ckap1 BG087395 Cytoskeleton-associated protein 1
Load more

Recommended publications
  • Paraspeckles: Possible Nuclear Hubs by the RNA for the RNA
    BioMol Concepts, Vol. 3 (2012), pp. 415–428 • Copyright © by Walter de Gruyter • Berlin • Boston. DOI 10.1515/bmc-2012-0017 Review Paraspeckles: possible nuclear hubs by the RNA for the RNA Tetsuro Hirose 1, * and Shinichi Nakagawa 2 Introduction 1 Biomedicinal Information Research Center , National Institute of Advanced Industrial Science and Technology, The eukaryotic cell nucleus is highly compartmentalized. 2-4-7 Aomi, Koutou 135-0064, Tokyo , Japan More than 10 membraneless subnuclear organelles have 2 RNA Biology Laboratory , RIKEN Advanced Research been identifi ed (1, 2) . These so-called nuclear bodies exist Institute, 2-1 Hirosawa, Wako 351-0198 , Japan in the interchromosomal space, where they are enriched in multiple nuclear regulatory factors, such as transcription and * Corresponding author RNA-processing factors. These factors are thought to serve e-mail: [email protected] as specialized hubs for various nuclear events, including transcriptional regulation and RNA processing (3, 4) . Some nuclear bodies serve as sites for the biogenesis of macromo- Abstract lecular machineries, such as ribosomes and spliceosomes. Multiple cancer cell types show striking alterations in their The mammalian cell nucleus is a highly compartmental- nuclear body organization, including changes in the numbers, ized system in which multiple subnuclear structures, called shapes and sizes of certain nuclear bodies (5) . The structural nuclear bodies, exist in the nucleoplasmic spaces. Some of complexity and dynamics of nuclear bodies have been impli- the nuclear bodies contain specifi c long non-coding RNAs cated in the regulation of complex gene expression pathways (ncRNAs) as their components, and may serve as sites for in mammalian cells.
    [Show full text]
  • Straightjacket/Α2δ3 Deregulation Is Associated with Cardiac Conduction Defects in Myotonic Dystrophy Type 1
    bioRxiv preprint doi: https://doi.org/10.1101/431569; this version posted October 2, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Straightjacket/α2δ3 deregulation is associated with cardiac conduction defects in Myotonic Dystrophy type 1 Emilie Plantié1, Masayuki Nakamori2, Yoan Renaud3, Aline Huguet4, Caroline Choquet5, Cristiana Dondi1, Lucile Miquerol5, Masanori Takahashi6, Geneviève Gourdon4, Guillaume Junion1, Teresa Jagla1, Monika Zmojdzian1* and Krzysztof Jagla1* 1 GReD, CNRS UMR6293, INSERM U1103, University of Clermont Auvergne, 28, Place Henri Dunant, 63000 Clermont-Ferrand, France 2 Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan 3 BYONET (www.byonet.fr) 4 Imagine Institute, Inserm UMR1163, 24, boulevard de Montparnasse, 75015 Paris, France 5 Aix-Marseille University, CNRS UMR7288, IBDM Luminy Campus Case 907, 13288 Marseille cedex 9, France 6 Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan • Correspondence to: Krzysztof Jagla [email protected] and Monika Zmojdzian [email protected] tel. +33 473178181; GReD, CNRS UMR6293, INSERM U1103, University of Clermont Auvergne, 28, Place Henri Dunant, 63000 Clermont-Ferrand, France 1 bioRxiv preprint doi: https://doi.org/10.1101/431569; this version posted October 2, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Cardiac conduction defects decrease life expectancy in myotonic dystrophy type 1 (DM1), a complex toxic CTG repeat disorder involving misbalance between two RNA- binding factors, MBNL1 and CELF1.
    [Show full text]
  • Supplemental Table 1A. Differential Gene Expression Profile of Adehcd40l and Adehnull Treated Cells Vs Untreated Cells
    Supplemental Table 1a. Differential Gene Expression Profile of AdEHCD40L and AdEHNull treated cells vs Untreated Cells Fold change Regulation Fold change Regulation ([AdEHCD40L] vs ([AdEHCD40L] ([AdEHNull] vs ([AdEHNull] vs Probe Set ID [Untreated]) vs [Untreated]) [Untreated]) [Untreated]) Gene Symbol Gene Title RefSeq Transcript ID NM_001039468 /// NM_001039469 /// NM_004954 /// 203942_s_at 2.02 down 1.00 down MARK2 MAP/microtubule affinity-regulating kinase 2 NM_017490 217985_s_at 2.09 down 1.00 down BAZ1A fibroblastbromodomain growth adjacent factor receptorto zinc finger 2 (bacteria-expressed domain, 1A kinase, keratinocyte NM_013448 /// NM_182648 growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer 203638_s_at 2.10 down 1.01 down FGFR2 syndrome, Jackson-Weiss syndrome) NM_000141 /// NM_022970 1570445_a_at 2.07 down 1.01 down LOC643201 hypothetical protein LOC643201 XM_001716444 /// XM_001717933 /// XM_932161 231763_at 3.05 down 1.02 down POLR3A polymerase (RNA) III (DNA directed) polypeptide A, 155kDa NM_007055 1555368_x_at 2.08 down 1.04 down ZNF479 zinc finger protein 479 NM_033273 /// XM_001714591 /// XM_001719979 241627_x_at 2.15 down 1.05 down FLJ10357 hypothetical protein FLJ10357 NM_018071 223208_at 2.17 down 1.06 down KCTD10 potassium channel tetramerisation domain containing 10 NM_031954 219923_at 2.09 down 1.07 down TRIM45 tripartite motif-containing 45 NM_025188 242772_x_at 2.03 down 1.07 down Transcribed locus 233019_at 2.19 down 1.08 down CNOT7 CCR4-NOT transcription complex, subunit 7 NM_013354
    [Show full text]
  • Table S3a Table
    Table S3a C2 KEGG Geneset Genesets enriched and upregulated in responders (FDR <0.25) Genesets enriched and upregulated in non-responders (FDR <0.25) HSA04610_COMPLEMENT_AND_COAGULATION_CASCADES HSA00970_AMINOACYL_TRNA_BIOSYNTHESIS HSA04640_HEMATOPOIETIC_CELL_LINEAGE HSA05050_DENTATORUBROPALLIDOLUYSIAN_ATROPHY HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION HSA04514_CELL_ADHESION_MOLECULES HSA04650_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY HSA04630_JAK_STAT_SIGNALING_PATHWAY HSA03320_PPAR_SIGNALING_PATHWAY HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION HSA00980_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 HSA00071_FATTY_ACID_METABOLISM HSA04660_T_CELL_RECEPTOR_SIGNALING_PATHWAY HSA04612_ANTIGEN_PROCESSING_AND_PRESENTATION HSA04662_B_CELL_RECEPTOR_SIGNALING_PATHWAY HSA04920_ADIPOCYTOKINE_SIGNALING_PATHWAY HSA00120_BILE_ACID_BIOSYNTHESIS HSA04670_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION HSA00641_3_CHLOROACRYLIC_ACID_DEGRADATION HSA04020_CALCIUM_SIGNALING_PATHWAY HSA04940_TYPE_I_DIABETES_MELLITUS HSA04512_ECM_RECEPTOR_INTERACTION HSA00010_GLYCOLYSIS_AND_GLUCONEOGENESIS HSA02010_ABC_TRANSPORTERS_GENERAL HSA04664_FC_EPSILON_RI_SIGNALING_PATHWAY HSA04710_CIRCADIAN_RHYTHM HSA04510_FOCAL_ADHESION HSA04810_REGULATION_OF_ACTIN_CYTOSKELETON HSA00410_BETA_ALANINE_METABOLISM HSA01040_POLYUNSATURATED_FATTY_ACID_BIOSYNTHESIS HSA00532_CHONDROITIN_SULFATE_BIOSYNTHESIS HSA04620_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY HSA04010_MAPK_SIGNALING_PATHWAY HSA00561_GLYCEROLIPID_METABOLISM HSA00053_ASCORBATE_AND_ALDARATE_METABOLISM HSA00590_ARACHIDONIC_ACID_METABOLISM
    [Show full text]
  • C/EBP ∆Uorf Mice – a Genetic Model for Uorf-Mediated Translational Control in Mammals
    Aus dem Max-Delbrück-Centrum für molekulare Medizin C/EBP uORF mice – a genetic model for uORF-mediated translational control in mammals Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) im Fach Biologie eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät I der Humboldt-Universität zu Berlin von Dr. med. Klaus Wethmar Präsident der Humboldt-Universität zu Berlin Prof. Dr. Dr. h.c. Christoph Markschies Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I Prof. Dr. Andreas Herrmann Gutachter: 1. Prof. Dr. Achim Leutz 2. Prof. Dr. Claus Scheidereit 3. Prof. Dr. Thomas Sommer Tag der mündlichen Prüfung: 28. März 2011 Table of contents Table of contents 2 Zusammenfassung 4 Abstract 5 Dedication 7 List of abbreviations 8 1 Introduction 11 1.1 Translational regulation of protein expression 11 1.1.1 Mechanisms of translational control 11 1.1.2 Translational control by upstream open reading frames 14 1.1.2.1 Variable presence of uORFs in alternative transcripts 15 1.1.2.2 Length, position and initiation codon context 15 1.1.2.3 Upstream ORFs integrate the general translational status of a cell 17 1.1.2.4 Upstream ORF-encoded peptides 18 1.1.2.5 Nonsense-mediated mRNA decay 19 1.1.2.6 Variables affecting the degree of uORF-mediated MCS repression 20 1.2 CCAAT/enhancer binding proteins 21 1.2.1 Family overview 21 1.2.2 Isoform-specific functions of C/EBP transcription factors 24 1.2.3 Upstream ORF-mediated control of C/EBP isoform expression 26 1.3 Aims of the thesis 29 2 Materials and Methods
    [Show full text]
  • The Emerging Role of the RBM20 and PTBP1 Ribonucleoproteins in Heart Development and Cardiovascular Diseases
    G C A T T A C G G C A T genes Review The Emerging Role of the RBM20 and PTBP1 Ribonucleoproteins in Heart Development and Cardiovascular Diseases Stefania Fochi, Pamela Lorenzi, Marilisa Galasso, Chiara Stefani , Elisabetta Trabetti, Donato Zipeto and Maria Grazia Romanelli * Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, 37134 Verona, Italy; [email protected] (S.F.); [email protected] (P.L.); [email protected] (M.G.); [email protected] (C.S.); [email protected] (E.T.); [email protected] (D.Z.) * Correspondence: [email protected]; Tel.: +39-045-802-7182 Received: 9 March 2020; Accepted: 6 April 2020; Published: 8 April 2020 Abstract: Alternative splicing is a regulatory mechanism essential for cell differentiation and tissue organization. More than 90% of human genes are regulated by alternative splicing events, which participate in cell fate determination. The general mechanisms of splicing events are well known, whereas only recently have deep-sequencing, high throughput analyses and animal models provided novel information on the network of functionally coordinated, tissue-specific, alternatively spliced exons. Heart development and cardiac tissue differentiation require thoroughly regulated splicing events. The ribonucleoprotein RBM20 is a key regulator of the alternative splicing events required for functional and structural heart properties, such as the expression of TTN isoforms. Recently, the polypyrimidine tract-binding protein PTBP1 has been demonstrated to participate with RBM20 in regulating splicing events. In this review, we summarize the updated knowledge relative to RBM20 and PTBP1 structure and molecular function; their role in alternative splicing mechanisms involved in the heart development and function; RBM20 mutations associated with idiopathic dilated cardiovascular disease (DCM); and the consequences of RBM20-altered expression or dysfunction.
    [Show full text]
  • Supplemental Solier
    Supplementary Figure 1. Importance of Exon numbers for transcript downregulation by CPT Numbers of down-regulated genes for four groups of comparable size genes, differing only by the number of exons. Supplementary Figure 2. CPT up-regulates the p53 signaling pathway genes A, List of the GO categories for the up-regulated genes in CPT-treated HCT116 cells (p<0.05). In bold: GO category also present for the genes that are up-regulated in CPT- treated MCF7 cells. B, List of the up-regulated genes in both CPT-treated HCT116 cells and CPT-treated MCF7 cells (CPT 4 h). C, RT-PCR showing the effect of CPT on JUN and H2AFJ transcripts. Control cells were exposed to DMSO. β2 microglobulin (β2) mRNA was used as control. Supplementary Figure 3. Down-regulation of RNA degradation-related genes after CPT treatment A, “RNA degradation” pathway from KEGG. The genes with “red stars” were down- regulated genes after CPT treatment. B, Affy Exon array data for the “CNOT” genes. The log2 difference for the “CNOT” genes expression depending on CPT treatment was normalized to the untreated controls. C, RT-PCR showing the effect of CPT on “CNOT” genes down-regulation. HCT116 cells were treated with CPT (10 µM, 20 h) and CNOT6L, CNOT2, CNOT4 and CNOT6 mRNA were analysed by RT-PCR. Control cells were exposed to DMSO. β2 microglobulin (β2) mRNA was used as control. D, CNOT6L down-regulation after CPT treatment. CNOT6L transcript was analysed by Q- PCR. Supplementary Figure 4. Down-regulation of ubiquitin-related genes after CPT treatment A, “Ubiquitin-mediated proteolysis” pathway from KEGG.
    [Show full text]
  • RNA-Protein Interaction Analysis of SARS-Cov-2 5'- and 3
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.05.425516; this version posted January 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 RNA-protein interaction analysis of SARS-CoV-2 5’- and 3’-untranslated 2 regions identifies an antiviral role of lysosome-associated membrane protein-2 3 4 Rohit Verma1,4, Sandhini Saha2,4, Shiv Kumar1, Shailendra Mani3, Tushar Kanti Maiti2, Milan 5 Surjit1* 6 7 1Virology Laboratory, Translational Health Science and Technology Institute, NCR Biotech 8 Science Cluster, Faridabad, 121001, Haryana, India. 9 10 2Laboratory of functional proteomics, Regional Centre for Biotechnology, NCR Biotech 11 Science Cluster, Faridabad, 121001, Haryana, India. 12 13 3Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 14 Faridabad, 121001, Haryana, India. 15 16 17 18 19 20 4contributed equally 21 22 * Correspondence: [email protected] 23 24 25 26 27 28 Keywords: SARS CoV-2; 5’-UTR; 3-UTR; RNA-protein interaction network; Coronavirus; 29 Virus-host interaction; Lamp2; Autophagy 30 31 32 33 34 35 36 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.05.425516; this version posted January 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 37 Abstract 38 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a positive-strand RNA 39 virus. Viral genome is capped at the 5’-end, followed by an untranslated region (UTR).
    [Show full text]
  • Transcriptomic Analysis of Patients with Tetralogy of Fallot Reveals the Effect of Chronic Hypoxia on Myocardial Gene Expression
    Ghorbel et al Congenital Heart Disease Transcriptomic analysis of patients with tetralogy of Fallot reveals the effect of chronic hypoxia on myocardial gene expression Mohamed T. Ghorbel, PhD, Myriam Cherif, PhD, Emma Jenkins, PhD, Amir Mokhtari, MRCS, Damien Kenny, MRCPCH, Gianni D. Angelini, FRCS, and Massimo Caputo, MD Objectives: In cyanotic patients undergoing repair of heart defects, chronic hypoxia is thought to lead to greater susceptibility to ischemia and reoxygenation injury. We sought to find an explanation to such a hypothesis by investigating the cardiac gene expression in patients with tetralogy of Fallot undergoing cardiac surgery. CHD Methods: The myocardial gene profile was investigated in right ventricular biopsy specimens obtained from 20 patients with a diagnosis of cyanotic (n ¼ 11) or acyanotic (n ¼ 9) tetralogy of Fallot undergoing surgical repair. Oligonucleotide microarray analyses were performed on the samples, and the array results were validated with Western blotting and enzyme-linked immunosorbent assay. Results: Data revealed 795 differentially expressed genes in cyanotic versus acyanotic hearts, with 198 upregu- lated and 597 downregulated. Growth/morphogenesis, remodeling, and apoptosis emerged as dominant func- tional themes for the upregulated genes and included the apoptotic gene TRAIL (tumor necrosis factor–related apoptosis-inducing ligand), the remodeling factor OPN (osteopontin), and the mitochondrial function gene COX11 (cytochrome-c oxidase 11). In contrast, transcription, mitogen-activated protein kinase signaling, and contractile machinery were the dominant functional classes for the downregulated genes, which included the calcium-handling gene NCX1 (sodium-calcium exchanger). Protein levels of COX11, NCX1, OPN, and LYZ (ly- sozyme) in the myocardium followed the same pattern obtained by means of transcriptomics.
    [Show full text]
  • Supplementary Data
    SUPPLEMENTAL INFORMATION A study restricted to chemokine receptors as well as a genome-wide transcript analysis uncovered CXCR4 as preferentially expressed in Ewing's sarcoma (Ewing's sarcoma) cells of metastatic origin (Figure 4). Transcriptome analyses showed that in addition to CXCR4, genes known to support cell motility and invasion topped the list of genes preferentially expressed in metastasis-derived cells (Figure 4D). These included kynurenine 3-monooxygenase (KMO), galectin-1 (LGALS1), gastrin-releasing peptide (GRP), procollagen C-endopeptidase enhancer (PCOLCE), and ephrin receptor B (EPHB3). KMO, a key enzyme of tryptophan catabolism, has not been linked to metastasis. Tryptophan and its catabolites, however, are involved in immune evasion by tumors, a process that can assist in tumor progression and metastasis (1). LGALS1, GRP, PCOLCE and EPHB3 have been linked to tumor progression and metastasis of several cancers (2-4). Top genes preferentially expressed in L-EDCL included genes that suppress cell motility and/or potentiate cell adhesion such as plakophilin 1 (PKP1), neuropeptide Y (NPY), or the metastasis suppressor TXNIP (5-7) (Figure 4D). Overall, L-EDCL were enriched in gene sets geared at optimizing nutrient transport and usage (Figure 4D; Supplementary Table 3), a state that may support the early stages of tumor growth. Once tumor growth outpaces nutrient and oxygen supplies, gene expression programs are usually switched to hypoxic response and neoangiogenesis, which ultimately lead to tumor egress and metastasis. Accordingly, gene sets involved in extracellular matrix remodeling, MAPK signaling, and response to hypoxia were up-regulated in M-EDCL (Figure 4D; Supplementary Table 4), consistent with their association to metastasis in other cancers (8, 9).
    [Show full text]
  • Molecular Mechanism and Metabolic Function of the S
    MOLECULAR MECHANISM AND METABOLIC FUNCTION OF THE S- NITROSO-COENZYME A REDUCTASE AKR1A1 by COLIN T. STOMBERSKI Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Advisor: Jonathan S. Stamler Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY May, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of COLIN T. STOMBERSKI candidate for the degree of Doctor of Philosophy*. Committee Chair Focco van den Akker Committee Members Jonathan Stamler George Dubyak Mukesh Jain Hung-Ying Kao 03-22-2019 *We also certify that written approval has been obtained for any proprietary material contained therein TABLE OF CONTENTS Table of Contents ………………………………………………………………………… i List of Tables ……………………………………………………………………………. v List of Figures ………………………………………………………………………….. vi List of Abbreviations …………………………………………………………………… ix Acknowledgements …………………………………………………………………….. xi Abstract ………………………………………………………………………………….. 1 Foundation and Experimental Framework ……………………………………………….. 3 Chapter 1: Protein S-nitrosylation: Determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling …………………………………………….. 5 1.1 Introduction …………………………………………………………………. 6 1.2 S-nitrosothiol specificity …………………………………………………….. 8 1.2.1 Acid-base and hydrophobic motifs ……………………………… 9 1.2.2 Interaction with nitric oxide synthases ………………………….. 13 1.3 S-nitrosothiol stability and reactivity ……………………………………….. 15 1.3.1 RSNO bond chemistry ………………………………………….. 16 1.3.2 Protein SNO—thiol reaction bias ………………………………. 18 1.3.3 SNO sites do not overlap S-oxidation sites …………………….. 19 1.4 Enzymatic denitrosylation ………………………………………………….. 20 1.4.1 The thioredoxin system ………………………………………… 21 1.4.2 LMW-SNO reductases …………………………………………. 23 1.4.3 The GSNO reductase system …………………………………… 24 1.4.4 GSNOR in physiology and pathophysiology …………………… 26 i 1.4.5 The SNO-CoA reductase system ……………………………….. 31 1.5 Specificity in denitrosylation ……………………………………………….
    [Show full text]
  • Molecular Basis of the Human Ribosomopathy Shwachman-Diamond Syndrome
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Apollo Advances in Biological Regulation 67 (2018) 109e127 Contents lists available at ScienceDirect Advances in Biological Regulation journal homepage: www.elsevier.com/locate/jbior Molecular basis of the human ribosomopathy Shwachman- Diamond syndrome * Alan J. Warren a, b, c, a Cambridge Institute for Medical Research, Cambridge, UK b The Department of Haematology, University of Cambridge, Cambridge, UK c Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UK article info abstract Article history: Mutations that target the ubiquitous process of ribosome assembly paradoxically cause Received 4 September 2017 diverse tissue-specific disorders (ribosomopathies) that are often associated with an Accepted 5 September 2017 increased risk of cancer. Ribosomes are the essential macromolecular machines that read Available online 6 September 2017 the genetic code in all cells in all kingdoms of life. Following pre-assembly in the nucleus, precursors of the large 60S and small 40S ribosomal subunits are exported to the cyto- Keywords: plasm where the final steps in maturation are completed. Here, I review the recent insights SBDS into the conserved mechanisms of ribosome assembly that have come from functional DNAJC21 eIF6 characterisation of the genes mutated in human ribosomopathies. In particular, recent Shwachman-Diamond syndrome advances in cryo-electron microscopy, coupled with genetic, biochemical and prior Ribosome structural data, have revealed that the SBDS protein that is deficient in the inherited Myelodysplastic syndromes leukaemia predisposition disorder Shwachman-Diamond syndrome couples the final step in cytoplasmic 60S ribosomal subunit maturation to a quality control assessment of the structural and functional integrity of the nascent particle.
    [Show full text]